Financials Alvotech Nyse

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.15 ^USD	+3.66%		+7.03%	+50.85%

Apr. 25	Cigna to offer Humira rivals with $0 copay at specialty pharmacy	RE
Apr. 24	Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	MT

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	308.8	2,486	3,048	3,956	-	-
Enterprise Value (EV) ¹	308.8	3,165	3,959	5,415	5,231	4,698
P/E ratio	-0.8 x	-3.85 x	-4.72 x	-23.7 x	136 x	20.8 x
Yield	-	-	-	-	-	1.31%
Capitalization / Revenue	8.4 x	29.9 x	32.6 x	12.3 x	6.52 x	4.54 x
EV / Revenue	8.4 x	38.1 x	42.4 x	16.9 x	8.63 x	5.4 x
EV / EBITDA	-	-9.71 x	-12 x	89.2 x	16.9 x	9.57 x
EV / FCF	-	-9.04 x	-11.5 x	111 x	25.8 x	12.6 x
FCF Yield	-	-11.1%	-8.72%	0.9%	3.88%	7.92%
Price to Book	-	-4.41 x	-2.8 x	-2.74 x	-4.19 x	-9.37 x
Nbr of stocks (in thousands)	31,250	248,650	265,530	279,567	-	-
Reference price ²	9.880	10.00	11.48	14.15	14.15	14.15
Announcement Date	5/10/22	3/1/23	3/20/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	36.77	83.03	93.38	321.1	606.4	870.5
EBITDA ¹	-	-326	-330.6	60.7	309.6	490.9
EBIT ¹	-	-346.4	-354.9	-25.28	233.7	410.7
Operating Margin	-	-417.25%	-380.01%	-7.87%	38.53%	47.18%
Earnings before Tax (EBT) ¹	-	-551.6	-651	-184.2	33.57	224.3
Net income ¹	-	-513.6	-551.7	-149.2	30.35	179.5
Net margin	-	-618.55%	-590.83%	-46.46%	5.01%	20.63%
EPS ²	-12.29	-2.600	-2.430	-0.5962	0.1037	0.6816
Free Cash Flow ¹	-	-350.3	-345.4	49	203	372
FCF margin	-	-421.86%	-369.9%	15.26%	33.48%	42.73%
FCF Conversion (EBITDA)	-	-	-	80.73%	65.57%	75.78%
FCF Conversion (Net income)	-	-	-	-	668.79%	207.2%
Dividend per Share ²	-	-	-	-	-	0.1850
Announcement Date	5/10/22	3/1/23	3/20/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q2
Net sales	-
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	189.3
Net margin	-
EPS ²	0.8500
Dividend per Share	-
Announcement Date	8/30/23

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	678	911	1,459	1,275	742
Net Cash position ¹	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-2.08 x	-2.755 x	24.04 x	4.119 x	1.512 x
Free Cash Flow ¹	-	-350	-345	49	203	372
ROE (net income / shareholders' equity)	-	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-72%	-62%	-12.2%	4.93%	13.4%
Assets ¹	-	713.2	889.3	1,225	616.3	1,343
Book Value Per Share ²	-	-2.270	-4.100	-5.160	-3.370	-1.510
Cash Flow per Share ²	-	-1.580	-1.370	0.2400	1.160	1.800
Capex ¹	-	37.9	33.2	32.1	7.76	7.76
Capex / Sales	-	45.62%	35.59%	10.01%	1.28%	0.89%
Announcement Date	5/10/22	3/1/23	3/20/24	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alvotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.15 USD

Average target price

16.5 USD

Spread / Average Target

+16.61%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.37%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research